FIELD: medicine.
SUBSTANCE: invention refers to biotechnology. The pharmaceutical composition for destruction of tumor cells expressing the receptor CCR7 is described, which contains an antibody binding to the receptor CCR7, and a pharmaceutically acceptable carrier. Versions of methods of eradication of tumor cells expressing the receptor CCR7 are proposed, which include either contacting of the specified cells with an antibody that binds with the specified receptor CCR7, or administering to the patient a therapeutically effective amount of an antibody that binds with the specified receptor CCR7.
EFFECT: invention expands the amount of means for cancer treatment.
6 cl, 8 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| ANTIBODIES SPECIFIC TO CLAUDIN 6 (CLDN6) | 2010 |
|
RU2675997C2 |
| ANTIBODIES TO OX-2/CD200 AND THEIR APPLICATION | 2007 |
|
RU2520088C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| BIOLOGICAL MATERIALS AND USE THEREOF | 2011 |
|
RU2593709C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| GENETICALLY MODIFIED GAMMA DELTA T CELLS | 2015 |
|
RU2756247C2 |
